

PALM BEACH COUNTY
BOARD OF COUNTY COMMISSIONERS
BOARD APPOINTMENT SUMMARY

Meeting Date: April 18, 2023

Department:
Submitted by: Community Services
Advisory Board: Palm Beach County HIV CARE Council

I. EXECUTIVE BRIEF

Motion and Title: Staff recommends motion to approve: the appointment of one (1) new member to the Palm Beach County HIV Comprehensive AIDS Resources Emergency (CARE) Council, effective April 18, 2023:

Table with 4 columns: Seat No., Appointment, Recommended By, Term Expires. Row 1: 4, Youssef Motii, HIV CARE Council, 04/17/2026

Summary: The Palm Beach County HIV CARE Council (HIV CARE Council) nomination process is an open process with publicized criteria and legislatively defined conflict of interest standards. Per Resolution No. R2018-0015, the total membership for the HIV CARE Council shall be no more than 33 at-large members. Mr.Motii has completed the HIV CARE Council's nomination process and the HIV CARE Council recommends the appointment. The diversity count for the 20 seats that are currently filled is African-American: 9 (45%), Caucasian: 5 (25%), Hispanic-American: 5 (25%) and Asian-American: 1 (5%). The gender ratio (female: male) is 11: 9. Mr. Motii is African-American. Staff conducts targeted outreach in an effort to proffer candidates for appointments that maintain a diverse composition of the board. (Ryan White Program) Countywide (HH)

Background and Justification: In accordance with the Ryan White CARE Act of 1990 (P.L.101-381), Palm Beach County was designated an eligible metropolitan area disproportionately affected by the HIV epidemic and having a demand for services exceeding the capacity of local resources to meet that demand. The Federal Government, through the Department of Health and Human Services, has made funds available to Palm Beach County to meet such demand. In order to access these funds, it is legally mandated by Title I (Part A) of the Ryan White Care Act that Palm Beach County designate a Title I (Part A) HIV Services Planning Council. The Board of County Commissioners established the Palm Beach County HIV CARE Council, per Resolution No. R2011-1560 dated October 18, 2011 and amended on January 23, 2018. The Ryan White CARE Act Amendments of 1996 mandate a nomination process for appointments to Title I (Part A) Planning Councils. As vacancies occur on the CARE Council, replacements are selected in accordance with the HIV CARE Council nominations process that was adopted and approved by the CARE Council on June 25, 2012.

- Attachments:
1. Boards/Committees Applications
2. HIV CARE Council Nominations Policy No. 10

Recommended By: James E. Green (signature) 3/22/2023
Department Director Date

Legal Sufficiency: Helene C. Skryd (signature) 3-23-23
Assistant County Attorney Date

PALM BEACH COUNTY
BOARD OF COUNTY COMMISSIONERS
BOARDS/COMMITTEES APPLICATION

The information provided on this form will be used in considering your nomination. Please COMPLETE SECTION II IN FULL. Answer "none" or "not applicable" where appropriate. Please attach a biography or resumé to this form.

Section I (Department): (Please Print)

Board Name: PBC HIV CARE COUNCIL Advisory Not Advisory

At Large Appointment or District Appointment /District #: _____

Term of Appointment: 3 Years. From: 04/18/2023 To: 04/17/2026

Seat Requirement: _____ Seat #: 4

*Reappointment or New Appointment

or to complete the term of _____ Due to: resignation other

Completion of term to expire on: _____

*When a person is being considered for reappointment, the number of previous disclosed voting conflicts during the previous term shall be considered by the Board of County Commissioners: _____

Section II (Applicant): (Please Print)

APPLICANT, UNLESS EXEMPTED, MUST BE A COUNTY RESIDENT

Name: Motii Youssef
Last First Middle

Occupation/Affiliation: Executive Director

Owner Employee Officer

Business Name: Oceana Community Health Inc

Business Address: 1050 Gateway Blvd, #101

City & State: Boynton Beach, FL Zip Code: 33426

Residence Address: 229 NW 15TH Street

City & State: Boca Raton, FL Zip Code: 33432

Home Phone: () Business Phone: (772) 255-3477 Ext. _____

Cell Phone: (561) 543-2236 Fax: (772) 255-3565

Email Address: admin@oceanhealth.org

Mailing Address Preference: Business Residence

Have you ever been convicted of a felony: Yes _____ No
If Yes, state the court, nature of offense, disposition of case and date: _____

Minority Identification Code: Male Female
 Native-American Hispanic-American Asian-American African-American Caucasian

Section II Continued:

CONTRACTUAL RELATIONSHIPS: Pursuant to Article XIII, Sec. 2-443 of the Palm Beach County Code of Ethics, advisory board members are prohibited from entering into any contract or other transaction for goods or services with Palm Beach County. Exceptions to this prohibition include awards made under sealed competitive bids, certain emergency and sole source purchases, and transactions that do not exceed \$500 per year in aggregate. These exemptions are described in the Code. This prohibition does not apply when the advisory board member's board provides no regulation, oversight, management, or policy-setting recommendations regarding the subject contract or transaction and the contract or transaction is disclosed at a public meeting of the Board of County Commissioners. **To determine compliance with this provision, it is necessary that you, as a board member applicant, identify all contractual relationships between Palm Beach County government and you as an individual, directly or indirectly, or your employer or business.** This information should be provided in the space below. If there are no contracts or transactions to report, please verify that none exist. Staff will review this information and determine if you are eligible to serve or if you may be eligible for an exception or waiver pursuant to the code.

<u>Contract/Transaction No.</u>	<u>Department/Division</u>	<u>Description of Services</u>	<u>Term</u>
<u>Example: (R#XX-XX/PO XX)</u>	<u>Parks & Recreation</u>	<u>General Maintenance</u>	<u>10/01/00-09/30/2100</u>
_____	_____	_____	_____
_____	_____	_____	_____
(Attach Additional Sheet(s), if necessary) OR			
NONE	<input checked="" type="checkbox"/>	NOT APPLICABLE/ (Governmental Entity)	

ETHICS TRAINING: All board members are required to read and complete training on Article XIII, the Palm Beach County Code of Ethics, and read the State Guide to the Sunshine Amendment. **Article XIII, and the training requirement can be found on the web at: <http://www.palmbeachcountyethics.com/training.htm>.** Ethics training is on-going, and pursuant to PPM CW-P-80 is required before appointment, and upon reappointment.

By signing below I acknowledge that I have read, understand the Sunshine Law Overview for Advisory Board Members and agree to abide by the Florida Sunshine Law and the Florida and Palm Beach County Code of Ethics, and I have received the required Ethics training (in the manner checked below):

By watching the training program on the Web, DVD or VHS on January 30 2023
 By attending a live presentation given on _____, 20____

AND

By signing below I acknowledge that I have read, understand and agree to abide by the Guide to the Sunshine Amendment & State of Florida Code of Ethics:

*Applicant's Signature: Youssef Motii Printed Name: Youssef Motii Date: 2023-01-30

Any questions and/or concerns regarding Article XIII, the Palm Beach County Code of Ethics, please visit the Commission on Ethics website www.palmbeachcountyethics.com or contact us via email at ethics@palmbeachcountyethics.com or (561) 233-0724.

Return this FORM to:
 {Insert Liaison Name Here}, {Insert Department/Division Here}
 {Insert Address Here}

Section III (Commissioner, if applicable):

Appointment to be made at BCC Meeting on: _____

Commissioner's Signature: _____ Date: _____

Pursuant to Florida's Public Records Law, this document may be reviewed and photocopied by members of the public.

Revised 01/09/2023

Youssef Motii, Ph.D.

Immunologist, PA-C Candidate



[linkedin.com/in/youssefmotii](https://www.linkedin.com/in/youssefmotii) | +1.561.543.2236 | youssef.motii@yale.edu

Education

Yale University, *Physician Associate*, M.MSc., Expected Graduation: 05/2025
2020- Florida Atlantic University, *Integrative Biology, Immunology* Ph.D., GPA: 4.0
2018- Florida Atlantic University, *Biomedical Science* M.S., GPA: 4.0
2016- Florida Atlantic University, *Biological Sciences* B.S., GPA: 3.67

Professional Experience

2022- *President and CEO*, Oceana Community Health, Inc
2021- *Patient Care Coordinator*, EliteMD Urgent Care, LLC
2021- *Community Care Consultant*, Boca Regional Pharmacy, LLC
2021- *Clinical Director*, Prestige Community Health Center, Inc
2021- *Regulatory Officer*, Oxygen Development, LLC
2021- *Associate*, Okeechobee Primary Care PA
2021- *Intern*, Hematology Oncology Associates of the Treasure Coast
2020- *Operations Officer*, KRS Global Biotechnology, Inc
2019- *Product Development Scientist*, KRS Global Biotechnology, Inc
2018- *Senior Researcher*, Cleveland Diabetes Care, Diabetic Retinopathy Laboratory
2018- *Intern*, Artificial Heart Project Engineering, Cleveland Heart
2017- *Research Associate*, Clinical Trial NCT-01606241, TapImmune, Inc
2016- *Community Outreach Analyst*, K&M Drugs, LLC
2016- *Founder*, Deetex Labs, LLC
2016- *Doctoral Researcher*, Cancer Immunotherapy Laboratory, Florida Atlantic University

Patents

2021- Provisional Patent 4.14/2 PROV Pending, "*Combinatorial Therapy for Use in Inducing Immunogenic Cell Death in Cancer Cells*"
2019- U.S. Patent Serial No.: 16/372,707 under Deetex Labs, LLC

Youssef Motii, Ph.D.

Immunologist, PA-C Candidate

[linkedin.com/in/youssefmotii](https://www.linkedin.com/in/youssefmotii) | +1.561.543.2236 | youssef.motii@yale.edu

Awards

- 2022- *Village Ambassador*, Village of Indiantown Village Council
- 2022- *Distinguished Researcher*, Theoria Medical™
- 2021- *Patient Care Advocate*, Cleveland Diabetes Care
- 2021- *Keynote Speaker*, University of Miami Sylvester Comprehensive Cancer Center
- 2021- *FAU Faculty INSPIRE Award*, Florida Atlantic University
- 2021- *3rd Place Research Poster*, 2021 Future of Immunology Research Symposium
- 2020- *Lead Owl*, Student Activities & Involvement-Florida Atlantic University
- 2020- *Community Caregiver*, United Way of Broward County
- 2020- *1st Place Poster Presentation*, Harvard Medical School BSCP Symposium
- 2020- *Finalist*, Three Minute Thesis (3MT®)- FAU College of Medicine
- 2019- *Volunteer of the Year*, ICNA Relief U.S.A
- 2019- *Excellence in Innovation Award*, KRS Global Biotechnology, Inc.
- 2019- *Magnanimous in Medicine*, Global Medical Brigades
- 2019- *People's Choice Finalist*, Three Minute Thesis (3MT®)- FAU College of Medicine
- 2019- *Venture 7 Class Award Winner*, FAU Innovation and Business Development
- 2018- *2nd Place Poster*, American Association for Cancer Research (AACR)
- 2018- *Doctoral Fellowship Grant*, FAU Foundation
- 2017- *Scholarship for Academic Excellence*, Marilyn and Jay Weinberg Foundation
- 2016- *Young Leaders Award*, Martin Luther King, Jr Foundation for Academic Achievement

Laboratory Skills and Experience

- Phlebotomy
- BLS certification
- Basic Diagnostics and Patient Intake
- Flow Cytometry and analysis
- Cell culture (2D and 3D)
- ELISA and Western blotting
- Fluorescent Spectrophotometry
- Bioinformatic analysis
- Cell cytotoxicity assay
- Tumorsphere cultivation
- CITI Animal Research aseptic surgery, injections, care, and euthanasia.
- Fluorescence-activated cell sorting (FACS) and Ficoll-Paque density gradient cell sorting
- Nanoparticle synthesis, delivery systems, and biochemistry
- Pharmacokinetic and Pharmacodynamic experimental design
- Fluorescence and Electron Microscopy

Youssef Motii, Ph.D.

Immunologist, PA-C Candidate

[linkedin.com/in/youssefmotii](https://www.linkedin.com/in/youssefmotii) | +1.561.543.2236 | youssef.motii@yale.edu

Research Experience

Hartmann (PI) 8/01/2019-12/06/2020

The trifecta: a novel combinatorial therapy spares immune cells while inducing immunogenic cell death in human mammary adenocarcinoma and mouse mammary carcinoma.

The goal of this study was to evaluate a novel combinatorial therapy in the treatment of human and mouse breast cancer and compare adverse toxicity of this treatment to that caused by conventional chemotherapeutic treatment.

Role: Co-PI

Hartmann (PI) 8/01/2018-7/01/2019

Development of a Multiplex Microparticle for Intracellular Immunotherapy of Breast Cancer.

The goal of this study was to enhance the drug-delivery system of a novel immunogenic cell death inducing agent to render a more targeted adaptive immune response and in turn contribute to tumor regression.

Role: Co-investigator

Hartmann (PI) 1/01/2016-7/01/2018

Synergistic effects of wogonin and glycolytic inhibitors against metastatic 4-T1 breast cancer cells.

The goal of this study is to evaluate the efficacy of these compounds against breast cancer cells when used in synergy.

Role: Co-investigator

Richardson (PI) 01/10/2018-12/20/2019

Evaluating the effects of gene therapy in the treatment of diabetic retinopathy.

The goal of this study was to evaluate the efficacy of a novel gene therapy in curing or slowing the progression of diabetic retinopathy in patients with diagnosed diabetes.

Role: Senior Researcher

Keating (PI) 01/04/2017-11/24/2017

TapImmune, Inc. Clinical Trial NCT-01606241

This Phase-1 clinical trial examined the effects of a novel adjuvant vaccine in the treatment of Stage 3 Double +/+ human mammary adenocarcinoma.

Role: Research Associate

Youssef Motii, Ph.D.

Immunologist, PA-C Candidate

linkedin.com/in/youssefmotii | +1:561.543.2236 | youssef.motii@yale.edu

Research Experience cntd.

Hartmann (PI)

9/01/2015-12/10/2016

The impact of pharmacological targeting of abnormal tumor metabolism with 3-Bromopyruvate on dendritic cell-mediated tumor immunity.

The goal of this study was to evaluate the ability of 3-bromopyruvate to induce immunogenic cell death in cancer cells, in turn activating tumor-specific dendritic cells and lymphocytes.

Role: Assistant Researcher

Hartmann (PI)

6/05/2015-5/01/2016

Immunotherapeutic vs chemotherapeutic drugs and their effects on cellular resistance mechanisms.

The goal of this study was to evaluate the efficacy of immunotherapeutic compounds versus standard chemotherapeutic compounds, as well as their ability to overcome resistance by the cancer cell.

Role: Co-investigator

Presentations

2021- Motii, Youssef. "Houdini: Tumor Cell Immune Evasion Mechanisms and TME Construct" Keynote Speaker. University of Miami Sylvester Comprehensive Cancer Center.

2021- Motii, Youssef. "Vitamin D, a.k.a. Steroid Hormone D" Keynote Speaker. Palm Beach County Wound Care. Jupiter Medical Center.

2020- Motii, Youssef and Hartmann, James. "The trifecta: a novel combinatorial therapy spares immune cells while inducing immunogenic cell death in human mammary adenocarcinoma and mouse mammary carcinoma" BSCP Research Symposium. Harvard Medical School.

2018- Motii, Youssef and Hartmann, James. "Evaluating the combinatorial effects of 2-deoxyglucose, wogonin, and methotrexate against metastatic breast cancer" Poster. Florida Atlantic University Graduate Research Symposium.

Youssef Motii, Ph.D.

Immunologist, PA-C Candidate

[linkedin.com/in/youssefmotii](https://www.linkedin.com/in/youssefmotii) | +1.561.543.2236 | youssef.motii@yale.edu

References

- James X. Hartmann, Ph.D., *Florida Atlantic University*
- Vijaya Iragavarapu-Charyulu, Ph.D., *Florida Atlantic University*
- Yoshimi Shibata, Ph.D., *Florida Atlantic University*
- David Binninger, Ph.D., *Florida Atlantic University*
- Rod Murphy, Ph.D., *Florida Atlantic University*
- Patricia Keating, Ph.D., *Florida Atlantic University*
- Scott Stanislaw, R.Ph, *KRS Global Biotechnology, Inc*
- Theodore Lampidis, Ph.D., *University of Miami Health System*
- Ira J. Gelb, MD, *Florida Atlantic University*
- Najum Choudhry, R.Ph, *Community Care Pharmacy, LLC*
- Charles Richardson, MD, *Cleveland Heart*
- Samarth Reddy, MD, *BRRH Oncology*
- Zahed Qureishi, MD, *Broward Health North*
- Uchechukwu K. Sampson, MD, *Cleveland Diabetes Care*
- Amjad Munim, MD, *Holy Cross Health*
- Mostafizur Rahman, MD, *George Washington University*
- Muhammad K Syed, MD, *Yale University*

Palm Beach County HIV CARE Council

CARE Council Policy

Policy Number: 10
Amended: June 24, 2019

Issue: **Nominations Process for CARE Council Membership**

This policy is adopted by the CARE Council (CARE Council), for the purpose of ensuring there is an open and fair nomination process which will provide for a CARE Council membership which is reflective of the AIDS epidemic in Palm Beach County, Florida. In addition, it is the intention of the CARE Council to maintain a nomination policy which complies with directives of the Division of HIV Services (DHS) and HRSA as those directives relate to the Ryan White Act.

I. Legislative Background

Section 2602(b) of the reauthorized Ryan White Act states: "Nominations to the planning council (CARE Council) shall be identified through an open process and candidates shall be selected based upon locally delineated and published criteria. Such criteria shall include a conflict of interest standard for each nominee."

II. Expectations

An open nominations process, in combination with other legislative requirements and existing DHS policy on PLWH participation, shall result in broad and diverse community inclusion and culturally competent deliberations in CARE Council processes. The CARE Council will only approve and/or appoint members who have gone through the nominations process and shall appoint members on a timely basis to ensure minimum disruption to CARE Council activities.

Nominations to the CARE Council shall be sought from a wide spectrum of potential members. Recruitment shall be made through existing CARE Council committees and through ongoing solicitation through existing CARE Council members, service providers, outreach through advertising, and staff working with consumers of HIV/AIDS services. Particular consideration shall be given to disproportionately affected and historically underserved groups and sub-populations.

Every member of the CARE Council is encouraged to actively recruit members to fill gaps in CARE Council membership. Recruitment is not just the Membership Committee's responsibility. CARE Council members should use their own network and seek key contacts in other communities to help identify potential members to fill gaps and to provide individuals to participate in CARE Council committee activities.

III. Steps in the Nominations Process:

1. When necessary advertising may be placed in various publications countywide notifying the public of the need for participation through membership on the CARE Council. Included in the advertising shall be notification of the need to fill membership positions based upon the demographics of the epidemic in Palm Beach County, and to ensure legislatively mandated positions are filled. A time limit for return of applications shall be included in the notification.
2. Potential applicants shall be invited to attend membership orientation offered quarterly and provided a nominations packet containing a letter describing roles and responsibilities of the CARE Council, duties of membership, time expectations, gaps in representations, conflict of interest standards, HIV disclosure requirements, and an overview of the selection process and timeline; within three (3) business days of request. There shall also be an application form used to gather information about: relevant experience, expertise, skills, the person's interest in serving, the perspective he or she might bring to the CARE Council, how his or her peer group might relate to groups affected by HIV, and other related information.
3. Each returned application will be issued a document number, and receipt shall be logged in for tracking purposes.
4. CARE Council staff will review all application forms and will recommend a list of persons for the Membership Committee to interview per "Procedure for Applicant Interviews". Interviews shall be conducted by at least two committee members- one of which must be the Chair or Vice Chair and a staff member, according to a structured interview format. Open ended questions about past experience on boards, ideas about significant HIV/AIDS issues and professional or affected community linkages shall be incorporated into the interview.
5. After the interviews are completed, the results of each interview are discussed at the next regularly scheduled Membership Committee meeting. When reviewing candidates for membership the committee will consider the following factors: attendance at CARE Council meetings, involvement at Membership Development Sessions and involvement on committees. The Membership Committee may also consider activities as involvement in Membership Development Sessions. In addition, seat availability, the demographics of the board and candidate qualification will be taken into consideration. The final committee recommendations will be forwarded to the CARE Council. If the